Find policies, billing codes, payers, states, and providers
Prostate Biopsy
Customize your policy alerts
Sign up for Aetna Policy 0698 alerts
Get alerted when Policy 0698 changes without checking for updates manually.
Monitor payer policy activity
Coverage policy for various prostate biopsy approaches (transperineal stereotactic template-guided saturation, transrectal ultrasound-guided, MRI-guided, and others) describing medical necessity, investigational procedures, coding guidance, and limitations for Aetna members and providers.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Medical necessity criteria by biopsy type
Covered when ANY of the specific procedural indications are met (grouped by biopsy type):
Saturation biopsy considered experimental/investigational for other indications (e.g., surveillance/watchful waiting).
MRI-guided biopsy criteria
Covered when ALL of the following are met for MRI-guided (transperineal or transrectal, in-bore or fusion) biopsy:
Includes in‑bore (direct) MRI-TB and MRI-TRUS fusion approaches; only suspicious lesions on mpMRI are targeted.
Documentation should include mpMRI lesion identification (e.g., PI-RADS) and prior biopsy history.
Re-biopsy selection
Coverage considerations for biopsy approaches in men with prior negative biopsies and persistent suspicion
NCCN and NICE guidance support considering saturation or transperineal/MRI approaches in selected re-biopsy cases; saturation reserved for repeated negatives.
Modality comparative outcomes
Comparative detection performance
Meta-analysis reported detection rates: TS-B 30.0%, TP-B 36.8%, MRI-B 37.6%; individual comparative studies report variable findings for combined strategies.
Harms and diagnostic consequences
Potential harms and downstream effects
Simon et al reported median cores ~64 with 45% cancer detection and notable hematuria; autopsy and cohort studies found no clear detection benefit over fewer cores and potential Gleason overestimation.
Adjunct/experimental methods
Adjunct and investigational technologies
These approaches are listed as experimental/investigational and not supported for routine clinical use in this policy.
Aetna considers the following procedures experimental and investigational because their effectiveness has not been established: contrast-enhanced ultrasound–targeted prostate biopsy, micro‑ultrasound (MicroUS) guided prostate biopsy (e.g., PRI‑MUS), spectral analysis of prostate tissue by fluorescence spectroscopy, and ultrasound superb microvascular imaging for guiding targeted prostate biopsy. These modalities remain investigational pending further evidence of clinical utility and standardized implementation.
Guidance indicates that transperineal template biopsy has a role in patients with prior negative or equivocal biopsies where diagnostic yield may be increased, but current evidence does not support its routine use as a mapping technique to determine exact tumor location and extent to guide focal therapy or as part of active surveillance. Use of transperineal template mapping for those purposes should be confined to settings with appropriate clinical governance, informed consent, audit, or research oversight.
Published studies of novel imaging‑guided biopsy approaches note several important limitations that affect interpretation and generalizability: operator and observer dependence (particularly for MicroUS interpretation), heterogeneity in MRI scanner strength and imaging protocols across centers, lack of standardized procedures for contrast‑enhanced ultrasound–guided biopsy, and absence of an ideal reference standard in some investigations. These factors reduce certainty about comparative performance and underscore the need for further standardized, multicenter validation with longer‑term outcomes.
Clinical Policy Bulletins are developed to assist in administering plan benefits and provide only a partial, general description of plan or program benefits. They do not constitute a contract or medical advice. Coverage determinations, exclusions, and any prior authorization requirements depend on the member’s specific plan documents and should be confirmed against the applicable plan language and administrative rules.
Transperineal stereotactic template‑guided saturation biopsy is medically necessary only for the specific indications listed in this policy (for example, men with two prior negative biopsies and persistently rising PSA, or men with prior biopsy showing atypia or high‑grade PIN). Use of transperineal stereotactic saturation biopsy for indications other than those specified in the policy (for example, routine surveillance or watchful waiting of persons with a known positive prostate biopsy) is considered experimental and investigational and is not supported by sufficient evidence.
Saturation biopsy protocols are not appropriate for initial screening or initial diagnostic biopsy. The policy and contemporary reviews indicate that saturation biopsy is intended primarily for re‑biopsy after prior negative TRUS biopsies when clinical suspicion persists. Initial diagnostic strategies should use extended schemes (e.g., 12 cores) or other standard approaches before considering a saturation protocol.
Coding Guidance
| 45342 | Sigmoidoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s). |
| 55706 | Biopsies, prostate, needle, transperineal, stereotactic template guided saturation sampling, including imaging guidance. |
| 72195 | Magnetic resonance (e.g. proton) imaging, pelvis. |
| 72196 | Magnetic resonance (e.g. proton) imaging, pelvis. |
| 72197 | Magnetic resonance (e.g. proton) imaging, pelvis. |
| 0443T | Real-time spectral analysis of prostate tissue by fluorescence spectroscopy, including imaging guidance. |
| G0416 | Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method. |
| C61 | Malignant neoplasm of prostate. |
| D07.5 | Carcinoma in situ of prostate [PIN III]. |
| N42.30 | Dysplasia of prostate [PIN I or II]. |
| Z12.5 | Encounter for screening for malignant neoplasm of prostate. |
| not specified | DSPA / know error® DNA specimen provenance assay (manufacturer-specific forensic DNA test) — described as laboratory quality control and not separately reimbursed |
| not specified | MRI-guided prostate biopsy (in-bore/direct MRI-TB, MRI/US fusion, cognitive fusion) — procedures and core counts vary by study |
| not specified | Saturation biopsy schemes (transrectal saturation biopsy TS-B, template transperineal saturation biopsy TTMB) — core counts in studies ranged from ~18 to ≥24 with some series reporting median cores up to 64 in very extensive protocols |
| not specified | Optical/fluorescence spectroscopy–guided biopsy needle and other experimental adjunct devices — described in small studies and considered investigational |
| No codes listed |
Provider Responsibilities and Billing Alerts
Codes affected by selection criteria
Certain CPT and HCPCS codes in this policy are covered only when the selection criteria in the policy are met. Verify that documentation supports the indication before billing these codes.
Prior authorization
This policy excerpt does not specify any formal prior authorization requirements. Providers should follow plan-specific prior authorization processes and any payer portals or instructions for submitting pre-service reviews when applicable.
- Prior authorization not specified in this excerpt
- No explicit prior authorization statement in the provided text
Prior authorization guidance
Clinical Policy Bulletins are administrative tools to assist in applying plan benefits. Providers are responsible for following the plan’s prior authorization processes and any submission instructions in network/practice-specific systems.
- Clinical Policy Bulletins assist in administering plan benefits — check plan portals for prior auth processes
- Providers are responsible for medical administration decisions and for obtaining any required authorizations per member plan
Investigational procedures — denial risk
Procedures identified as experimental or investigational in this policy may be denied as not medically necessary. Ensure that indications and supporting evidence are documented if performing or billing for these procedures.
- Experimental/Investigational (denial risk): Contrast‑enhanced ultrasound‑targeted prostate biopsy
- Experimental/Investigational (denial risk): Micro‑ultrasound guided prostate biopsy (e.g., PRI‑MUS)
- Experimental/Investigational (denial risk): Real‑time spectral analysis of prostate tissue by fluorescence spectroscopy (0443T)
- Experimental/Investigational (denial risk): Ultrasound superb microvascular imaging for targeted biopsy
DSPA / know error® reimbursement stance
The know error® DNA Specimen Provenance Assay (DSPA) is considered part of the laboratory’s quality control and is not separately reimbursed. Do not bill this test as a separately reimbursable service when performed as part of biopsy specimen processing.
- DSPA/know error® reimbursement stance: not separately reimbursed; considered laboratory quality control
- Treat as integral to the biopsy/pathology workflow; include in laboratory service bundle billing when applicable
Clinical indication and biopsy sequencing documentation
Document the clinical indication clearly in the medical record to support medical necessity for biopsy procedures. Include prior biopsy history, reason for re‑biopsy, PSA trends, DRE findings, and any atypia or PIN on prior pathology when applicable.
- Clinical indication documentation should include: number and results of prior biopsies, PSA trend (rising/values), DRE findings, and prior histologic findings (atypia or high‑grade PIN)
- Preferred biopsy sequencing: reserve saturation biopsies (≥20 cores) for patients with repeated negative biopsies but persistent high suspicion
Documentation for MRI‑guided and re‑biopsy procedures
When MRI‑guided biopsy techniques or re‑biopsy strategies are used, document prior TRUS biopsies (if performed), rationale for choosing MRI‑GB or transperineal approaches, mpMRI findings (including PI‑RADS score), and whether in‑bore, fusion, or cognitive targeting was used.
- Documentation for MRI‑guided and re‑biopsy procedures: prior negative TRUS biopsies (when applicable) and clinical rationale for re‑biopsy
- Documentation of pre‑biopsy mpMRI findings: record PI‑RADS scoring and the MRI‑targeting method (in‑bore, fusion, cognitive)
Background and Scope
Prostate cancer is a common malignancy and tissue diagnosis requires biopsy. Transperineal stereotactic template‑guided saturation biopsy (TTSB) is an approach that samples the gland extensively; series and guideline descriptions characterize typical sampling schemes in the range of about 30–80 cores in saturation or extensive template protocols. TTSB is proposed principally for men with prior negative biopsies but persistent clinical suspicion (for example, rising PSA, atypia, or high‑grade PIN), where more extensive sampling may improve detection of clinically significant disease.
Key Definitions
Policy Revision History
Policy effective date as listed in document metadata.
Most recent policy review date recorded in document metadata.
Next scheduled policy review date recorded in document metadata.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.